Piramal
knowledge action care

February 11, 2013

Corporate Relationship Department,
BSE Limited
New Trading Wing,
Rotunda Building, P.J. Towers,
Dalal Street, Fort,
Mumbai- 400 001.

Fax No. 22723121 / 22721072
22722037

The Market Operations Department,
National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No.C/1, G.Block
Bandra-Kurla Complex, Bandra (E)
Mumbai- 400 051.

Fax No. 26598237 / 26598238

Dear Sir / Madam,

Sub: Outcome of Board Meeting held on February 11, 2013: Financial Results (consolidated and standalone) for the quarter and nine months ended December 31, 2012;

Kindly refer to our letter dated February 1, 2013 on the subject.

At the Board Meeting held today, the Board approved the Unaudited Financial Results (consolidated and standalone) of the Company for the quarter and nine months ended December 31, 2012. The said results have been reviewed by the Auditors of the Company and a copy of their Limited Review Report is enclosed.

A Press Release being issued in this regard is also enclosed.

Kindly note that as informed vide our letter dated July 21, 2009 and February 1, 2013, the Company shall be publishing only the consolidated financial results in the newspapers in accordance with clause 41(VI)(b) of the Listing Agreement.

Kindly take the above on record.

Thanking you,

Yours sincerely,
For **Piramal Enterprises Limited**
(formerly Piramal Healthcare Limited)

Leonard D'Souza
Company Secretary

c.c. to: National Securities Depository Ltd., Mumbai
Central Depository Services (India) Ltd., Mumbai

The Board of Directors
Piramal Enterprises Limited
Lower Parel,
Mumbai – 400 013.
India.

1. We have reviewed the consolidated results of Piramal Enterprises Limited (formerly known as Piramal Healthcare Limited), its subsidiaries, jointly controlled entity and associate company hereinafter referred to as the "Group" for the quarter ended December 31, 2012 which are included in the accompanying "Statement of Consolidated ..." (the "Statement"), except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' in Piramal Enterprises Limited which have been traced from disclosures made by the Management but have neither been reviewed nor been audited by us. The Statement has been prepared by the Group's Management pursuant to Clause 41 of the Listing Agreement with the Stock Exchanges in India, which has been initialled by us for identification purposes. This Statement is the responsibility of the Group's Management and has been approved by the Board of Directors on the ... Enterprises Limited ... January 31, 2013.

2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement.

3. A review is limited primarily to inquiries of group's personnel and analytical procedures applied to group's financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

4. We have only traced the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' in Piramal Enterprises Limited in the Statement from the disclosures made by the Group's Management and are, therefore, not expressing a review opinion thereon.

5. We did not review the financial results/ statements of (i) 45 subsidiaries and 1 jointly controlled entity considered in the preparation of the Statement and which constitute total revenue of Rs. 651.91 Crores and Rs. 1,627.91 Crores and net profit of Rs. 97.05 Crores and Rs. 62.00 Crores for the quarter and period then ended, respectively, which have been reviewed by other auditors/ certified by the management whose reports have been furnished to us, and our opinion on the Statement to the extent they have been derived from such financial results/ statements is based solely on the report of such other auditors/ management returns.

Price Waterhouse
Chartered Accountants
FRN 301112E
Mumbai

6. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the [illegible] practices and policies, and has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Price Waterhouse
Firm Registration Number: 301112E
Chartered Accountants

Vilas Rane
Partner
Membership Number: 33220

Mumbai
February 11, 2013

Piramal | Healthcare

knowledge action care

PIRAMAL ENTERPRISES LIMITED

(Formerly known as PIRAMAL HEALTHCARE LIMITED)

[illegible]

STATEMENT OF CONSOLIDATED UNAUDITED RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2012

(Rs. in Lakhs)

Particulars	3 months ended	Preceding 3 months ended	Corresponding 3 months ended in the previous year	Year to date figures for current period ended	Year to date figures for previous year ended	Previous Year ended
	31/12/2012 (Unaudited)	30/09/2012 (Unaudited)	31/12/2011 (Unaudited)	31/12/2012 (Unaudited)	31/12/2011 (Unaudited)	31/03/2012 (Audited)
Income from operations						
Net Sales / Income from Operations (Net of excise duty)	98,100	89,074	96,832	286,941	147,974	210,979
Other Operating Income / Unallocated Income	3,167	3,417	2,775	3,431	18,002	24,254
Total Income from Operations (Net)	99,267	92,491	99,707	290,372	165,976	235,233
Expenses						
Cost of Materials Consumed	25,256	25,853	23,419	75,418	69,842	93,033
Purchase of Stock-in-Trade	6,078	7,381	20,775	60,155	31,469	43,642
Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	5,823	5,626	4,877	15,887	5,565	12,929
Employee Benefits Expense	8,764	8,519	12,068	26,610	17,861	23,313
Other Expenses	20,996	20,636	24,428	69,189	42,268	56,301
Total Expenses	66,917	68,015	84,892	255,259	167,005	329,998
Profit / (Loss) from operations before other income, finance costs and exceptional items	32,350	24,476	(21,185)	35,113	(1,029)	(94,765)
Other Income	6,149	2,449	2,797	14,588	20,696	27,677
Profit / (Loss) from ordinary activities before finance costs and exceptional items	38,499	26,925	(18,388)	49,701	19,667	(67,088)
Finance Costs	14,050	11,323	7,719	38,008	22,873	36,201
Profit / (Loss) from ordinary activities after finance costs but before exceptional items	24,449	15,602	(26,107)	11,693	(3,206)	(103,289)
Exceptional Items (Net)	262	32	253	440	362	566
Profit / (Loss) from ordinary activities before tax	24,187	15,570	(26,360)	11,253	(3,568)	(103,855)
Tax Expenses (Net of Deferred Tax)	518	1,462	(3,776)	2,005	1,671	560
Net Profit / (Loss) from ordinary activities after tax	23,669	14,108	(22,584)	9,248	(5,239)	(104,415)
Extraordinary Items (Net of Tax Expense)	-	-	-	-	-	-
Net Profit / (Loss) for the period before minority interest	23,669	14,108	(22,584)	9,248	(5,239)	(104,415)
Share of profit / (loss) of associates (Net of Tax Expense)	(124)	(99)	-	(213)	-	-
Minority Interest Profit / (Loss)	154	(37)	114	243	240	376
Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates	23,639	14,046	(22,698)	9,218	(5,479)	(104,791)
Paid-up equity share capital (Face Value Rs.2/- each)	3,451	3,451	3,451	3,451	3,451	3,451
Reserve (excluding Revaluation Reserves)						1,130,752
Earnings per share						
a) Consolidated Basic and diluted EPS before extraordinary items for the period (Rs.)	3.5	(5.3)	0.5	(1.6)	9.0	6.6
b) Consolidated Basic and diluted EPS after extraordinary items for the period (Rs.)	3.5	(5.3)	0.5	(1.6)	9.0	6.6

PART II						
a) Pledged/Encumbered						
- Number of shares	-	-	-	-	-	-
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-	-	-
- Percentage of shares (as a % of the total share capital of the company)	-	-	-	-	-	-
b) Non-encumbered						
- Number of shares	91,436,297	91,536,372	91,601,222	91,436,297	91,601,222	91,580,997
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
- Percentage of shares (as a % of the total share capital of the company)	52.99%	53.05%	53.08%	52.99%	53.08%	53.07%

Particulars	3 months ended 31/12/2012
B. INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	1
Received during the quarter	1
Disposed of during the quarter	1
Remaining unresolved at the end of the quarter	1

PIRAMAL ENTERPRISES LIMITED * MUMBAI

Price Waterhouse Chartered Accountants FRN 301112E Mumbai

Piramal Enterprises Limited
A Wing 6th Floor 247 Park LBS Marg Vikhroli West Mumbai 400 083
D +91 22 3095 6666 F +91 22 3095 6665
W www.piramalhealthcare.com

Piramal | Healthcare
knowledge action care

Segment Wise Revenue, Results and Capital Employed

(Rs. in Lakhs)

	3 Months ended	Preceding 3 months ended	Corresponding 3 months ended in the previous year	Year to date figures for current period ended	Year to date figures for previous year ended	Previous Year ended
	31/12/2012	30/09/2012	31/12/2011	31/12/2012	31/12/2011	31/03/2012
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1. Segment Revenue						
Total Income from Operations (Net)						
a. Pharmaceuticals manufacturing and services	[illegible]	[illegible]	[illegible]	20,356	20,427	29,709
c. Information management	28,492	17,445	-	49,519	-	-
Total	59,857	86,492	61,757	269,572	166,436	235,233
Less: Inter Segment revenue	-	-	-	-	-	-
Total Income from Operations (Net)	59,357	86,492	61,757	269,572	166,436	235,233
2. Segment Results						
(Profit / (Loss) before Tax, Finance Cost and Exceptional Item)						
a. Pharmaceuticals manufacturing and services	(2,415)	(4,461)	(10,417)	(10,949)	(17,486)	(21,587)
b. Financial services including strategic investments	4,178	1,079	7,022	8,743	19,000	14,112
c. Information management	9,440	1,418	-	12,144	-	-
Total	11,183	(1,964)	(3,395)	9,938	1,514	(7,555)
Add : Exchange Gain (Net)	6,143	2,687	2,797	14,588	20,694	27,874
Less: Finance Cost - (INTEREST LIABILITIES)						
a. Pharmaceuticals manufacturing and services	148,369	171,915	135,261	148,369	135,261	114,199
b. Financial services including strategic investments	958,371	945,387	1,023,259	958,371	1,023,259	1,011,047
c. Information management	21,873	13,254	-	21,873	-	-
Total Capital Employed	1,126,613	1,130,556	1,158,520	1,126,613	1,158,520	1,125,237

PIRAMAL ENTERPRISES LIMITED * MUMBAI

Price Waterhouse Chartered Accountants FRN 301112E Mumbai

[illegible]

Piramal | Healthcare
knowledge action care

7. The figures for the quarter and nine months ended December 31, 2011 and for the year ended March 31, 2012 have been regrouped, wherever necessary.

Ajay G. Piramal
Chairman

February 11, 2013, Mumbai

Price Waterhouse
Chartered Accountants
FRN 301112E
Mumbai

The Board of Directors
Piramal Enterprises Limited
Piramal Tower,
Ganpatrao Kadam Marg,
Lower Parel,
Mumbai – 400 013,
India.

1. We have reviewed the results of Piramal Enterprises Limited (the "Company") (formerly known as accompanying 'Statement of Standalone Unaudited Results for the quarter and nine months ended December 31, 2012' (the "Statement"), except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the Management but have neither been reviewed nor been audited by us. The Statement has been prepared by the Company pursuant to Clause 41 of the Listing Agreement with the Stock Exchanges responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.

2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement.

3. A review is limited primarily to inquiries of company personnel and analytical procedures applied to accordingly, we do not express an audit opinion

4. We have only traced the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' in the Statement from the disclosures made by the Management and are, therefore, not expressing a review opinion thereon.

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the applicable Accounting Standards notified pursuant to the Companies (Accounting Standards) Rules, 2006 as per Section 211(3C) of the Companies Act, 1956 and other recognised accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Price Waterhouse
Firm Registration Number: 301112E
Chartered Accountants

Vilas Rane

Piramal | Healthcare

Transforming Lives

PIRAMAL ENTERPRISES LIMITED
(Formerly known as PIRAMAL HEALTHCARE LIMITED)
Piramal House, Peninsula Corporate Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai - 400013

STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2012

(Rs. in Lakhs)

PART I	Quarter ended	Preceding 3 months ended	Corresponding 3 months ended in the previous year	Year to date figures for current period	Year to date figures for previous period	Previous Year ended
	31/12/2012 (Unaudited)	30/09/2012 (Unaudited)	31/12/2011 (Unaudited)	31/12/2012 (Unaudited)	31/12/2011 (Unaudited)	31/03/2012 (Audited)
Income from operations						
Net Sales / Income from Operations (Net of excise duty)	46,183	32,550	29,069	101,165	80,602	109,625
Other Operating Income/Investment Income	6,345	5,801	7,277	17,334	22,396	31,193
Total Income from Operations (Net)	52,528	38,351	36,346	118,499	102,998	140,818
Expenses						
Cost of Materials Consumed / Purchases of Stock-in-Trade	2,204	2,382	2,025	6,054	6,971	8,096
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(174)	(2,806)	202	(2,917)	(2,807)	(1,251)
Employee benefits expense	4,292	5,171	3,670	13,628	11,456	15,175
Depreciation and amortisation expense	1,313	2,053	2,666	5,928	5,710	7,636
Research and Development Expenses	6,199	6,966	10,879	16,694	12,076	16,787
Other Expenses (Net)	40,728	30,977	41,180	118,669	99,643	136,675
Total Expenses	54,562	44,743	60,622	158,056	133,039	183,118
Profit / (Loss) from operations before other income, finance costs and exceptional items	(2,034)	(6,392)	(24,276)	(39,557)	(30,041)	(42,300)
Other Income	9,330	2,932	2,187	14,831	20,783	27,973
Profit / (Loss) from ordinary activities before finance costs and exceptional items	7,296	(3,460)	(22,089)	(24,726)	(9,258)	(14,327)
Finance Costs	10,704	6,524	1,983	23,458	4,268	19,990
Profit / (Loss) from ordinary activities after finance costs but before exceptional items	(3,408)	(9,984)	(24,072)	(48,184)	(13,526)	(34,317)
Exceptional Items	(4,029)	-	-	(4,029)	33,375	46,439
Profit / (Loss) from ordinary activities before tax	(7,437)	(9,984)	(24,072)	(52,213)	19,849	12,122
Tax Expense (Net of Deferred Tax)	(1,159)	154	(3,967)	(381)	834	(950)
Net Profit / (Loss) from ordinary activities after tax	(6,278)	(10,138)	(20,105)	(51,832)	19,015	13,072
Net Profit / (Loss) for the period	(6,278)	(10,138)	(20,105)	(51,832)	19,015	13,072
Paid-up Equity Share Capital (Face Value Rs.2/- each)	3,451	3,451	3,451	3,451	3,451	3,451
Reserves (Excluding Revaluation Reserves)						1,110,627
Paid-up Debt Capital						15,000
Debenture Redemption Reserve						3,000
Earnings Per Share (EPS)						
a) Basic and diluted EPS before extraordinary items for the period (Rs.)	(1.4)	(3.5)	(0.4)	(4.6)	11.3	7.7
b) Basic and diluted EPS after extraordinary items for the period (Rs.)	(1.4)	(3.5)	(0.4)	(4.6)	11.3	7.7

PART II						
A. PARTICULARS OF SHAREHOLDING						
1. Public Shareholding						
- Number of shares	81,124,803	81,026,628	80,961,878	81,124,803	80,961,878	80,982,103
- Percentage of shareholding	47.01%	46.95%	46.92%	47.01%	46.92%	46.93%
2. Promoters and Promoter group Shareholding						
a) Pledged/Encumbered						
- Number of shares	-	-	-	-	-	-
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-	-	-
- Percentage of shares (as a % of the total share capital of the company)	-	-	-	-	-	-
b) Non-encumbered						
- Number of Shares	91,438,297	91,536,272	91,601,222	91,438,297	91,601,222	91,580,997
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
- Percentage of shares (as a % of the total share capital of the company)	52.99%	53.05%	53.08%	52.99%	53.08%	53.07%
Pending at the beginning of the quarter		1				
Received during the quarter		1				
Disposed of during the quarter		1				
Remaining unresolved at the end of the quarter		1				

PIRAMAL ENTERPRISES LIMITED ★ MUMBAI

Price Waterhouse Chartered Accountants FRN 301112E Mumbai

Piramal Enterprises Limited
A Wing 6th Floor 247 Park LBS Marg Vikhroli West Mumbai 400 083
D +91 22 3095 6666 F +91 22 3095 6665
W www.piramalhealthcare.com

Segment Wise Revenue, Results and Capital Employed

(Rs. in Lakhs)

	3 months ended	Preceding 3 months ended	Corresponding 3 months ended in the previous year	Year to date figures for current period ended	Year to date figures for previous year ended	Previous Year ended
	31/12/2012	30/09/2012	31/12/2011	31/12/2012	31/12/2011	31/03/2012
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1. Segment Revenue						
Total Income from Operations (Net)						
a. Pharmaceuticals manufacturing and services	33,494	30,931	29,705	97,021	82,754	112,208
b. Financial Services including Strategic Investments	8,082	7,168	8,641	21,472	20,244	28,610
Less: Inter Segment Revenue	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
Total Income from Operations (Net)	41,576	38,099	38,346	118,493	102,998	140,818
2. Segment Results						
(Profit / (Loss) before Tax, Finance Cost and Exchange Gain)						
a. Pharmaceuticals manufacturing and services	(7,305)	(9,043)	(11,445)	(21,643)	(16,908)	(24,468)
b. Financial Services including Strategic Investments	2,069	3,356	6,641	8,791	20,244	15,303
Total	(5,236)	(5,687)	(4,804)	(12,852)	3,336	(9,165)
Add : Exchange Gain (Net)	8,139	2,931	2,187	14,909	20,781	27,970
Less: Finance Cost	8,731	2,919	1,983	10,777	4,268	6,683
Total Profit / (Loss) Before Tax	(5,828)	(5,675)	(4,600)	(8,720)	19,849	12,122
3. Capital Employed						
(Segment assets - Segment liabilities)						
a. Pharmaceuticals manufacturing and services	33,210	74,950	90,474	33,210	91,717	57,769
b. Financial Services including Strategic Investments	1,072,929	1,033,667	1,064,646	1,072,929	1,064,646	1,056,709
Total Capital Employed in the Company	1,106,139	1,108,617	1,155,120	1,106,139	1,155,120	1,114,078

PIRAMAL ENTERPRISES LIMITED ★ MUMBAI

Price Waterhouse ★ Chartered Accountants ★ FRN 301112E Mumbai

Piramal | Healthcare
knowledge action care

Notes:

1. The standalone financial results for the quarter and nine months ended December 31, 2012, have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on February 11, 2013.

2. The figures for the quarter ended December 31, 2012 are not comparable to the previous quarter ended December 31, 2011 on account of demerger of New Chemical Entity (NCE) unit of Piramal Life Sciences Limited (PLSL) into the Company during the previous year.

3. The Company has not recognized deferred tax asset on the tax losses in absence of virtual certainty for creditability of taxable profits in the foreseeable future.

4. At its meeting held on November 5, 2012, the Board of Directors had approved the merger of PHL Holdings Private Limited (PHPL) into the Company with effect from January 01, 2013 (Appointed Date). As per the Scheme, existing equity shares held by PHPL in the Company will be cancelled and equivalent number of equity shares will be issued by the Company to the equity shareholder of PHPL as consideration for the merger. All costs arising out of or incurred in connection with the Scheme shall be borne by PHPL and / or its shareholders and no costs shall be borne by the Company. The Scheme is subject to approval of the shareholders and sanction by the Hon'ble Bombay High Court.

5. The figures for the quarter and nine months ended December 31, 2011 and for the year ended March 31, 2012 have been regrouped, wherever necessary.

For PIRAMAL ENTERPRISES LIMITED

February 11, 2013, Mumbai.

Price Waterhouse
Chartered Accountants
FRN 301112E
Mumbai

Press Release

Piramal Enterprises announces Q3 FY2013 result

Total operating income up by 61% to ₹ 994 Cr,

Mumbai, February 7, 2013: Piramal Enterprises Limited ("PEL", NSE: PEL, BSE: 500302) today announced results for Q3 FY2013.

For the quarter ended Q3 FY2013, the Total operating income showed strong growth of 60.9% to ₹ 993.6 Cr against ₹ 617.6 Cr in Q3FY2012. Operating Profit (OPBITDA) for the quarter grew to ₹ 206.7 Cr in Q3FY2013 as compared with ₹ 8.7 Cr during the same period last year. Similarly, the Operating profit margin for the quarter was higher at 20.8% as compared to 1.4% in Q3FY2012. Net Profit for the quarter was ₹ 63.8 Cr as compared with net profit of ₹ 9.7 Cr during Q3FY2012.

9M FY2013 performance:

Total operating income for 9MFY2013 was up by 56.6% to ₹ 2,605.7 Cr. The Operating Profit for the period was higher at ₹ 360.2 Cr against ₹ 114.4 Cr in 9MFY2012. The Operating profit margin for 9MFY2013 was 13.8% as compared to 6.9% in 9MFY2012. The results for the period include the financial results of DRG and NCE unit. DRG acquisition was completed in June 2012 while NCE unit was demerged into PEL in Q3FY2012. For the 9M FY2013, PEL reported a Net Loss of ₹ 22.3 Cr as 9MFY2013 as compared with ₹ 52.8 Cr in 9M FY2012. As of December 2012, the total debt stood at ₹ 7,358.7 Cr raised to fund acquisition of DRG & Abacus International and to fund growth of PHL Finance.

During 9M FY2013, Pharma Solutions business grew by 16.7% to ₹ 1,123.2 Cr against ₹ 962.5 Cr in 9MFY2012. The revenues from overseas facilities recorded strong growth of 21.2% to ₹ 458.9 Cr over 9MFY2012. Critical Care business grew by 65.9% to ₹ 465.6 Cr over 9MFY2012. OTC & Ophthalmology business recorded sales of ₹ 208.3 Cr registering growth of 22.7% during 9MFY2013.

For the nine months ended December 2012, income from financial services business (PHL Finance and INDIAREIT) was ₹ 248.8 Cr. The loan book as on 31st December 2012 was ₹ 1,349 Cr. Piramal's real estate PE firm - INDIAREIT term sheeted exits worth ₹ 440 Cr across three earlier funds and a third party mandate during Q3 FY2013.

The revenues from Decision Resources Group Inc. were ₹ 495.2 Cr for 9M FY2013. DRG continued to achieve a high customer retention rate of over 96% in 2012 and has retained all 2011 top 20

For further information on the financials, please visit our website: www.piramalenterprises.com

*****

Note to the Editors:

About the Piramal Group
The Piramal Group, led by Ajay G. Piramal is one of India's foremost business conglomerates. Driven by the core values of Knowledge Action Care, the Piramal Group has interests in a myriad of industries that encompass healthcare, drug discovery & research, diagnostics, glass, real estate and financial services. The Piramal Group steadfastly pursues inclusive growth while adhering to ethical

About Piramal Enterprises Ltd.
Piramal Enterprises is one of India's largest diversified companies, with a presence in pharmaceutical, financial services and information management sectors. Piramal Enterprises had consolidated revenues of $ 500 million in FY2012. In the pharmaceutical space, PEL is one of leading custom manufacturing player globally, has presence in the global critical care segment with a portfolio of inhalation and injectible anesthetics and its OTC business is ranked no. 7 in India. PEL is also engaged in drug discovery & research and has strong pipeline of development products. In the financial services space, PEL has a real estate focused PE fund – Indiareit and a NBFC that is focused on lending to real estate and education sector. Recently, PEL has also entered the global information management industry through acquisition of a US based company - Decision Resources Group.

For investor enquiries, please contact:
Mr. Jatin Lal / Prasad Mhatre
Investor Relations Team,
Piramal Enterprises Limited.

For media enquiries, please contact:

PIRAMAL ENTERPRISES LIMITED	**PUBLIC RELATIONS AGENCY**
Akansha Pradhan / Riddhi Goradia	Janhavi Bellare / Rakesh Reddy
Corporate Communications,	Hanmer MSL
Piramal Group	Tel: +91-22-6633 5969
Contact: +91 22 3351 4082 / 4083	Mobile: +91 9322854508 / +91 9321735515
akansha.pradhan@piramal.com	Janhavi.bellare@hanmermsl.com
riddhi.goradia@piramal.com	rakesh.reddy@hanmermsl.com